DE2253086A1 - Preservation of biological materials - such as organs and tissues and infusion solutions using heavy water - Google Patents

Preservation of biological materials - such as organs and tissues and infusion solutions using heavy water

Info

Publication number
DE2253086A1
DE2253086A1 DE19722253086 DE2253086A DE2253086A1 DE 2253086 A1 DE2253086 A1 DE 2253086A1 DE 19722253086 DE19722253086 DE 19722253086 DE 2253086 A DE2253086 A DE 2253086A DE 2253086 A1 DE2253086 A1 DE 2253086A1
Authority
DE
Germany
Prior art keywords
heavy water
organs
preservation
tissues
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19722253086
Other languages
German (de)
Other versions
DE2253086B2 (en
DE2253086C3 (en
Inventor
Martin Prof Dr Wenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19722253086 priority Critical patent/DE2253086C3/en
Publication of DE2253086A1 publication Critical patent/DE2253086A1/en
Publication of DE2253086B2 publication Critical patent/DE2253086B2/en
Application granted granted Critical
Publication of DE2253086C3 publication Critical patent/DE2253086C3/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Solns. or media or infusion purposes or for the storage of organs, tissues, tissue parts, proteins or enzymes contain heavy water as sovlent. The heavy water, which is pref. present in a concentration of 7-25%, gives improved resistance to biological degradation such as protein denaturation. A special application is in the perfusion of organs intended for transplant purposes. A further application is in the preservation of sera, blood preparations, and enzymes.

Description

Lösungen zur Infusion und zur Aufbewahrung von Geweben oder Gewebeteilen.Solutions for infusion and storage of tissues or parts of tissues.

Es ist bekannt, Lösungen für Körperinfusionen mit geigneten Ionen und Nährstoffen zu versehen.It is known solutions for body infusions with suitable ions and to provide nutrients.

So können derartige Lösungen im einfacheren Fall einen Gehalt von 0,9% besitzen; sie können aber auch eine Vielzahl vQn Ionen, Glukose, Serui-vemß sowie weitere Blutbestandteile gelöst enthalten. Ähnliche Lösungen verwendet man zur in-vitro Behandlung von überlebendex Gewebe z.B. für Zellkulturen oder zur Konservierung von vitalen Organen. In sämtlichen Fällen dient als Lösungsmittel für die zu lösenden Stoffe normales Wasser, manchmal mit geringen Anteilen von Glycerin.In the simpler case, such solutions can have a content of Own 0.9%; But they can also contain a multitude of ions, glucose, serum as well as other blood components in dissolved form. Similar solutions are used for in-vitro treatment of surviving ex tissue e.g. for cell cultures or for preservation of vital organs. In all cases serves as a solvent for the to be dissolved Substances normal water, sometimes with small amounts of glycerine.

Es wurde nun gefunden, daß derartige Lösungen oder Medien biologische Objekte wie Zellen, Organe und den Gesamtorganismus gegen Schädigungen besser konservieren, wenn dem üblichen Lösungsmittel Wasser (H2O) ein Anteil von 2-99,9» schweren naser (D2O) zugesetzt wird. Als besonders vorteilhafter Konzentrations bereich tat sich ein Schwerwasser - Anteil von 7-25% erwiesen. Die Stabilisierung bio@logischer Systeme nimmt bis zu einet Schwerwasser - Anteil von 10-15 besonders stark zu. bine weitere Erhöhung der Schwerwasserkonzentration führt zwar zu winer weiteren Brhöhung der biologischen Stabilisierung , der relative Effekt ist aber geringer. It has now been found that such solutions or media are biological Better preserve objects such as cells, organs and the entire organism against damage, if the usual solvent water (H2O) has a proportion of 2-99.9 »heavy naser (D2O) is added. It turned out to be a particularly advantageous concentration range a heavy water share of 7-25% has been proven. The stabilization of bio @ logical systems up to a heavy water share of 10-15 increases particularly strongly. bine more Increasing the heavy water concentration leads to winer further Brhöhen the biological stabilization, but the relative effect is less.

Manchmal wird man zweckmäßigerweise den Schwert wasser - Anteil im primären Medium so hoch bemessen, daß die Schwerwasserkonzentration nach Verdünnung durch den Wasseranteil im Gewebe wieder 7-25* beträgt. Sometimes you will expediently the sword water - share in the primary medium so high that the heavy water concentration after dilution due to the water content in the fabric is again 7-25 *.

Die erfindungsgemäß D2O - haltigen Lösungen erlauben di. Konservierung der nativen biologischen Eigenschaften von Zellen und Organen über einen Längeren Zeitraum als im entsprechenden H20 - Medium. Bine spezielle Anwendung ist das Durchstromen von Organen, die zu Transplantationszwec@en konserviert werden sollen.The solutions containing D2O according to the invention allow di. Preservation the native biological properties of cells and organs for a long time Period than in the corresponding H20 medium. A special application is through-flow of organs that are to be preserved for transplantation purposes.

Dabei kann mit der erfindungsgemäßen Lösung, die noch zusätzlich Blutanteile gelöst oder in suspension enthalten kann, den Organen zusätzlich Sauerstoff zugeführt werden.With the solution according to the invention, the additional blood components dissolved or contained in suspension, the organs are additionally supplied with oxygen will.

Eine weitere Anwendung ergibt sich bei der Konservierung von Seren, Blutkonserven und Enzymen und ähnlichen biologisebem material, das im Laufe der Zeit oder durch zu hohe oder zu tiefe Temperaturen denaturieft werden.Another application is the preservation of serums, Donated blood and enzymes and similar biological material, which in the course of the Time or be denatured by temperatures that are too high or too low.

Auch hierbei ist die Effektivität einer D2O- Konzentration Bereich von 7-25% besonders ausgeprägt.Here, too, the effectiveness of a D2O concentration is in the range from 7-25% particularly pronounced.

Claims (1)

Patentansprsiche:Claims: Anspruch 1 Lösungen oder Medien zu Infusionszwecken oder zur Aufbewahrung von Organen und Geweben sowie Gewebeteilen, Eiweißen oder Enzymen dadurch gekennzeichnet, daß sie als Lösungsmittel Schweres Wasser enthalten.Claim 1 solutions or media for infusion purposes or for storage of organs and tissues as well as tissue parts, proteins or enzymes characterized by that they contain heavy water as a solvent. Anspruch 2: Lösungen oder Medien gemäß Anspruch 1 dadurch gekennzeichnet, daß sie einen Schwerwasseranteil von 7-25* enthalten.Claim 2: Solutions or media according to Claim 1, characterized in that that they contain a heavy water content of 7-25 *. Anspruch 3: Lösungen oder Medien zu Infusionszwecken dadurch gekennzeichnet, daß der Schwerwasseranteil so bemessen ist, daß nach Verdünnung durch den Wassergehalt der zu konseryierenden Organe oder nach Mischung mit Flüssigkeittailen des Organismus ein Bchwerwassergehalt von 7-25% erreicht wird.Claim 3: Solutions or media for infusion purposes, characterized in that that the heavy water content is such that after dilution by the water content of the organs to be preserved or after mixing with fluid tails of the organism a heavy water content of 7-25% is achieved. Anspruch 4: Lösungen zur Konservierung von Seren, Eiweiß und Enzymen und ähnlichen denaturierbaren Materialien dadurch gekennzeichnet, daß sie als Lösungsmittel einen Anteil von Schwerwasser enthalten.Claim 4: Solutions for the preservation of serums, protein and enzymes and similar denaturable materials characterized in that they are used as solvents contain a proportion of heavy water.
DE19722253086 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts Expired DE2253086C3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19722253086 DE2253086C3 (en) 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19722253086 DE2253086C3 (en) 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Publications (3)

Publication Number Publication Date
DE2253086A1 true DE2253086A1 (en) 1974-05-09
DE2253086B2 DE2253086B2 (en) 1978-06-15
DE2253086C3 DE2253086C3 (en) 1979-02-15

Family

ID=5860372

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19722253086 Expired DE2253086C3 (en) 1972-10-25 1972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Country Status (1)

Country Link
DE (1) DE2253086C3 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045769A2 (en) * 1998-03-10 1999-09-16 Imperial College Of Science, Technology And Medicine Preservation solution
US9717822B2 (en) 2007-06-15 2017-08-01 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US10028837B2 (en) 2007-07-10 2018-07-24 Warsaw Orthopedic, Inc. Delivery system attachment
US10098681B2 (en) 2009-02-12 2018-10-16 Warsaw Orthopedic, Inc. Segmented delivery system
US10220115B2 (en) 2007-06-15 2019-03-05 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
US10328179B2 (en) 2005-11-01 2019-06-25 Warsaw Orthopedic, Inc. Bone matrix compositions and methods

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049220A1 (en) 1999-12-30 2001-07-12 Osteotech, Inc. Intervertebral implants
US20030120274A1 (en) 2000-10-20 2003-06-26 Morris John W. Implant retaining device
US6855167B2 (en) 2001-12-05 2005-02-15 Osteotech, Inc. Spinal intervertebral implant, interconnections for such implant and processes for making
US8328876B2 (en) 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
EP1708651A4 (en) 2004-01-27 2011-11-02 Osteotech Inc Stabilized bone graft
CA2677903A1 (en) 2007-02-12 2008-08-21 Osteotech, Inc. Joint revision implant
WO2008157492A2 (en) 2007-06-15 2008-12-24 Osteotech, Inc. Osteoinductive demineralized cancellous bone
WO2008157497A2 (en) 2007-06-15 2008-12-24 Osteotech, Inc. Method of treating tissue
WO2009052492A2 (en) 2007-10-19 2009-04-23 Osteotech, Inc. Demineralized bone matrix compositions and methods

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045769A2 (en) * 1998-03-10 1999-09-16 Imperial College Of Science, Technology And Medicine Preservation solution
WO1999045769A3 (en) * 1998-03-10 1999-11-04 Imperial College Preservation solution
US10328179B2 (en) 2005-11-01 2019-06-25 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US9717822B2 (en) 2007-06-15 2017-08-01 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US10220115B2 (en) 2007-06-15 2019-03-05 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
US10357511B2 (en) 2007-06-15 2019-07-23 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US10028837B2 (en) 2007-07-10 2018-07-24 Warsaw Orthopedic, Inc. Delivery system attachment
US10098681B2 (en) 2009-02-12 2018-10-16 Warsaw Orthopedic, Inc. Segmented delivery system

Also Published As

Publication number Publication date
DE2253086B2 (en) 1978-06-15
DE2253086C3 (en) 1979-02-15

Similar Documents

Publication Publication Date Title
DE2253086A1 (en) Preservation of biological materials - such as organs and tissues and infusion solutions using heavy water
Gasic et al. Removal of sialic acid from the cell coat in tumor cells and vascular endothellum, and its effects on metastasis
Williams Origin of transmembrane potentials in non-excitable cells
Relman The physiological behavior of rubidium and cesium in relation to that of potassium
Lamson et al. Studies on shock induced by hemorrhage
CA2119554C (en) Method and compositions with aldehyde stabilizing solution
Nasakina et al. Biocompatibility of nanostructured nitinol with titanium or tantalum surface composite layers formed by magnetron sputtering
Whittembury et al. Electrical potential difference measurements in perfused single proximal tubules of Necturus kidney
DE102008039734A1 (en) Stabilization of cells by ionic liquids
Burton The roles of buffers in body fluids: mathematical analysis
Rosenshtraukh et al. Studies of energy transport in heart cells: The effect of creatine phosphate on the frog ventricular contractile force and action potential duration
Sinex et al. Isolation of gelatin from ancient bones
Feuvray et al. Effect of short dimethylsulfoxide perfusions on ultrastructure of the isolated rat heart
Evans Some histological findings in spontaneously preserved bodies
CN112425603B (en) Transportation and preservation solution for adipose-derived stem cells
CN114609205A (en) Preparation method of reference electrode for implanting electrochemical biosensor
Robinson et al. Comparison of the protective properties of four clinical crystalloid cardioplegic solutions in the rat heart
Harada et al. Stimulation of renin secretion from the intact kidney and from isolated glomeruli by the calcium ionophore A23187
de Paula et al. The use of fixative solutions throughout the ages: a comprehensive review
US3256151A (en) Process for preparing calcitonin
Shuttleworth et al. Cyclic AMP and ouabain‐binding sites in the rectal gland of the dogfish Scyliorhinus canicula
Srii et al. Bee honey as a locum for routine formalin fixative
Chick et al. Membrane potential in human teeth: The effect of some common organic anions
Pine et al. Anion exchange and volume regulation during metabolic blockade of renal cortical slices.
Ponder The permeability of human red cells to cations after treatment with resorcinol, n-butyl alcohol, and similar lysins

Legal Events

Date Code Title Description
OGA New person/name/address of the applicant
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee